MedTrace Logo

Testing BRCA 1/2 Mutation Using Next Generation Sequencing

NCT02151747 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2019-10-07

No results posted yet for this study

Summary

Testing BRCA 1/2 mutation is important for patients with breast cancer, and Sanger sequencing is a standard method to identify BRCA 1/2 mutation. Next generation sequencing (NGS) is a high-throughput parallel sequencing that can provide genetic information with high accuracy. NGS is a faster and cost-effective method to detect gene mutations compared to Sanger sequencing. In this study, we evaluated the clinical role of NGS testing for BRCA 1/2 compared to Sanger sequencing.

Conditions

Sponsors & Collaborators

  • Severance Hospital

    lead OTHER

Principal Investigators

  • Seung IL Kim, MD, phD · Yonsei University

  • JH Sohn, MD,phD · Yonsei University

  • Hyung Seok Park, MD · Yonsei University

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02151747 on ClinicalTrials.gov